Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amphastar Pharmaceuticals Inc (AMPH) vs Arqit Quantum Inc (ARQQ) Price & Performance

Amphastar Pharmaceuticals IncTrade
Arqit Quantum IncTrade

Price performance (Past 24H)

Key statistics

Amphastar Pharmaceuticals Inc vs Arqit Quantum Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Arqit Quantum Inc trades at $24.06 (market cap $392.69M). The key difference: Amphastar Pharmaceuticals Inc is far larger — about 2.2× Arqit Quantum Inc's market cap. Which is the better fit depends on your goals.

AMPHARQQ
Market Cap
$863.95M$392.69M
Sector
HealthTechnology
52-Week High
$30.81$58.27
52-Week Low
$16.87$11.78
Enterprise Value
$1.26B$366.00M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amphastar Pharmaceuticals Inc

AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.

Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.

Arqit Quantum Inc

ARQQ trades at $22.90, up 6.66% with bullish technical signals from moving averages and ADX indicators. The company shows explosive revenue growth (829% YoY in H1 FY26) but remains deeply unprofitable with a -4,508% net margin and negative cash flow from operations. Recent news highlights quantum-safe encryption partnerships and government contract wins, though financial sustainability concerns persist.

The stock presents high-risk speculation on quantum security adoption versus fundamental weaknesses. Upside depends on commercializing technology into sustainable profits, while downside risks include cash burn and competitive threats. Analyst consensus is split 50/50 buy/hold with no institutional conviction evident in current financial metrics.

Returns comparison

Trailing returns across standard periods

About Amphastar Pharmaceuticals Inc

Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.

Read more on AMPH

About Arqit Quantum Inc

Arqit Quantum provides advanced cybersecurity software that uses symmetric key agreement technology. Its solutions protect networked devices and data against current and future cyber threats, including quantum attacks.

Read more on ARQQ